| pubmed-article:19010673 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19010673 | lifeskim:mentions | umls-concept:C0108066 | lld:lifeskim |
| pubmed-article:19010673 | lifeskim:mentions | umls-concept:C0243076 | lld:lifeskim |
| pubmed-article:19010673 | lifeskim:mentions | umls-concept:C0205250 | lld:lifeskim |
| pubmed-article:19010673 | lifeskim:mentions | umls-concept:C1880355 | lld:lifeskim |
| pubmed-article:19010673 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:19010673 | pubmed:dateCreated | 2008-12-26 | lld:pubmed |
| pubmed-article:19010673 | pubmed:abstractText | Rational modification of a previously identified spirohydantoin lead structure has identified a series of potent spiroazaoxindole CGRP receptor antagonists. The azaoxindole was found to be a general replacement for the hydantoin that consistently improved in vitro potency. The combination of the indanylspiroazaoxindole and optimized benzimidazolinones led to highly potent antagonists (e.g., 25, CGRP K(i)=40pM). The closely related compound 27 demonstrated good oral bioavailability in dog and rhesus. | lld:pubmed |
| pubmed-article:19010673 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19010673 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19010673 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:19010673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19010673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19010673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19010673 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19010673 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:19010673 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:19010673 | pubmed:issn | 1464-3405 | lld:pubmed |
| pubmed-article:19010673 | pubmed:author | pubmed-author:KaneStefanie... | lld:pubmed |
| pubmed-article:19010673 | pubmed:author | pubmed-author:BednarRodney... | lld:pubmed |
| pubmed-article:19010673 | pubmed:author | pubmed-author:SalvatoreChri... | lld:pubmed |
| pubmed-article:19010673 | pubmed:author | pubmed-author:StumpCraig... | lld:pubmed |
| pubmed-article:19010673 | pubmed:author | pubmed-author:WilliamsThere... | lld:pubmed |
| pubmed-article:19010673 | pubmed:author | pubmed-author:BellIan MIM | lld:pubmed |
| pubmed-article:19010673 | pubmed:author | pubmed-author:GallicchioSte... | lld:pubmed |
| pubmed-article:19010673 | pubmed:author | pubmed-author:GrahamSamuel... | lld:pubmed |
| pubmed-article:19010673 | pubmed:author | pubmed-author:JohnstonVicto... | lld:pubmed |
| pubmed-article:19010673 | pubmed:author | pubmed-author:VaccaJoseph... | lld:pubmed |
| pubmed-article:19010673 | pubmed:author | pubmed-author:FayJohn FJF | lld:pubmed |
| pubmed-article:19010673 | pubmed:author | pubmed-author:MosserScott... | lld:pubmed |
| pubmed-article:19010673 | pubmed:author | pubmed-author:ThebergeCory... | lld:pubmed |
| pubmed-article:19010673 | pubmed:author | pubmed-author:QuigleyAmy... | lld:pubmed |
| pubmed-article:19010673 | pubmed:author | pubmed-author:MooreEric LEL | lld:pubmed |
| pubmed-article:19010673 | pubmed:author | pubmed-author:ZhangXu-FangX... | lld:pubmed |
| pubmed-article:19010673 | pubmed:author | pubmed-author:BrunoJoseph... | lld:pubmed |
| pubmed-article:19010673 | pubmed:author | pubmed-author:Blair... | lld:pubmed |
| pubmed-article:19010673 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:19010673 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:19010673 | pubmed:volume | 19 | lld:pubmed |
| pubmed-article:19010673 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19010673 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19010673 | pubmed:pagination | 214-7 | lld:pubmed |
| pubmed-article:19010673 | pubmed:meshHeading | pubmed-meshheading:19010673... | lld:pubmed |
| pubmed-article:19010673 | pubmed:meshHeading | pubmed-meshheading:19010673... | lld:pubmed |
| pubmed-article:19010673 | pubmed:meshHeading | pubmed-meshheading:19010673... | lld:pubmed |
| pubmed-article:19010673 | pubmed:meshHeading | pubmed-meshheading:19010673... | lld:pubmed |
| pubmed-article:19010673 | pubmed:meshHeading | pubmed-meshheading:19010673... | lld:pubmed |
| pubmed-article:19010673 | pubmed:meshHeading | pubmed-meshheading:19010673... | lld:pubmed |
| pubmed-article:19010673 | pubmed:meshHeading | pubmed-meshheading:19010673... | lld:pubmed |
| pubmed-article:19010673 | pubmed:meshHeading | pubmed-meshheading:19010673... | lld:pubmed |
| pubmed-article:19010673 | pubmed:meshHeading | pubmed-meshheading:19010673... | lld:pubmed |
| pubmed-article:19010673 | pubmed:meshHeading | pubmed-meshheading:19010673... | lld:pubmed |
| pubmed-article:19010673 | pubmed:meshHeading | pubmed-meshheading:19010673... | lld:pubmed |
| pubmed-article:19010673 | pubmed:year | 2009 | lld:pubmed |
| pubmed-article:19010673 | pubmed:articleTitle | The discovery of highly potent CGRP receptor antagonists. | lld:pubmed |
| pubmed-article:19010673 | pubmed:affiliation | Department of Medicinal Chemistry, Merck & Co, Inc, West Point, PA 19486, USA. craig_stump@merck.com | lld:pubmed |
| pubmed-article:19010673 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:19010673 | lld:chembl |
